CAR T Cells | CHOP Research Institute

CAR T Cells

Published on
Sep 8, 2023
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”). 

Published on
Mar 28, 2022
The Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy is a first-of-its-kind hub for pediatric Cancer Immunotherapy.
Published on
Feb 3, 2022
Two patients infused with CAR T-cell therapy one decade ago remain in remission with detectable levels of cancer-fighting cells.
Published on
Jan 24, 2022
Researchers identified aberrant splicing as a culprit behind treatment resistance in B-ALL.
Published on
Jan 3, 2022
Congratulations to Garrett Brodeur, MD, recipient of the American Society of Pediatric Hematology/Oncology Distinguished Career Award.
Published on
Dec 15, 2021
Dr. Mark Yarmarkovich, PhD, a senior scientist at CHOP, is a 2021 STAT Wunderkind.
Published on
Jul 9, 2021
This week’s news roundup features new findings in youth suicide risk, CAR T-cell therapy, obesity rates during the pandemic, and more.

Research in the Tasian Laboratory focuses on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.

Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.

fosterjb [at]